+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times?



Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times?



Circulation 90(3): 1550-1551




(PDF emailed within 0-6 h: $19.90)

Accession: 009702256

Download citation: RISBibTeXText

PMID: 8087961

DOI: 10.1161/01.cir.90.3.1550


Related references

Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. Jacc. Heart Failure 4(2): 152-158, 2016

Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure. Casopis Lekaru Ceskych 154(6): 269-271, 2016

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). European Journal of Heart Failure 15(9): 1062-1073, 2014

Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. Bmc Medicine 13: 35-35, 2015

Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. Psychosomatic Medicine 77(7): 808-815, 2016

Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. International Journal of Cardiology 56(3): 283-288, 1996

Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 18(7): 859-868, 2016

Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation 134(22): 1785-1787, 2016

Why do patients fail to receive beta-blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of beta-blocker therapy in patients with chronic heart failure. American Heart Journal 149(5): 921-926, 2005

Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity-matched study of multimorbidity in chronic heart failure. International Journal of Cardiology 134(3): 330-335, 2010

Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European Journal of Heart Failure 15(10): 1157-1163, 2014

Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan: Chronic heart failure analysis registry in Tohoku district (CHART). Circulation Journal 67(5): 431-436, 2003

Vascular extracellular superoxide dismutase activity in patients with chronic heart failure; relationship to endothelium-dependent vasodilation A new mechanism for endothelial dysfunction in chronic heart failure?. European Heart Journal 21(Abstract Supplement): 387, August-September, 2000